Literature DB >> 15713998

The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.

Yoshiyuki Mori1, Koji Kono, Yoshirou Matsumoto, Hideki Fujii, Tetsu Yamane, Masako Mitsumata, Wen-Tien Chen.   

Abstract

OBJECTIVE: The invasion and metastasis of carcinoma cells require the proteolytic degradation of the extracellular matrix by various cell surface proteases. Among these, seprase is a type II transmembrane serine protease absent in normal tissues and it has been implicated in the invasion of the extracellular matrix by both tumor and stromal cells in human breast carcinoma and melanoma. In the present study, the expression of seprase mRNA, protein and its gelatin-degrading activity in human gastric carcinoma were examined to substantiate the potential role of seprase in gastric carcinoma invasion.
METHODS: We have examined the seprase expression in human gastric carcinoma (n = 34) by RT-PCR, Western immunoblotting analysis, immunohistochemistry, and gelatin zymography.
RESULTS: Immunoblotting analysis using mAb D8 directed against seprase showed that the carcinoma tissues in 26 out of 34 cases of gastric cancer expressed a dimeric form of seprase but their normal counterparts did not. Gelatin zymography confirmed that the isolated seprase exhibited the gelatin-degrading activity and was active. Seprase-expressing carcinoma tissues were more often found in the scirrhous type than in other types of gastric carcinoma. RT-PCR analysis showed that seprase mRNA was present in carcinoma tissues but not in normal tissues. Immunohistochemically, seprase was mainly located in gastric carcinoma cells, weakly in stromal cells and microvessel endothelial cells in the tumor nest, and none in normal cells.
CONCLUSIONS: Our studies showed the unique expression and localization of seprase in the tumor and stromal cells within human gastric carcinoma but not in normal tissues, suggesting a role of seprase in the invasive and metastatic progression of gastric carcinoma. Copyright (c) 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15713998     DOI: 10.1159/000082926

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  23 in total

1.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

2.  [Construction of a eukaryotic expression vector of fibroblast activation protein and establishment of its stable over-expression in the oral squamous cell carcinoma].

Authors:  Zhao Meng; Shao Tingru; Huang Jiaxin; Chen Yuechuan; Lv Xiaozhi
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-10-01

Review 3.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

4.  Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.

Authors:  Min Shi; Dang-Hui Yu; Ying Chen; Chen-Yan Zhao; Jing Zhang; Qing-Hua Liu; Can-Rong Ni; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

5.  Activation of EDTA-resistant gelatinases in malignant human tumors.

Authors:  Donghai Chen; Alanna Kennedy; Jaw-Yuan Wang; Wei Zeng; Qiang Zhao; Michael Pearl; Mengzhen Zhang; Zhenhe Suo; Jahn M Nesland; Yuhuan Qiao; Ah-Kau Ng; Naoko Hirashima; Tetsu Yamane; Yoshiyuki Mori; Masako Mitsumata; Giulio Ghersi; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

Review 6.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

7.  Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.

Authors:  Paulette Mhawech-Fauceglia; Li Yan; Maryam Sharifian; Xing Ren; Song Liu; Grace Kim; Simon A Gayther; Tanja Pejovic; Kate Lawrenson
Journal:  Cancer Microenviron       Date:  2014-10-21

8.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices.

Authors:  Giulio Ghersi; Qiang Zhao; Monica Salamone; Yunyun Yeh; Stanley Zucker; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 9.  Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms.

Authors:  Suzanne Eccles; Lenaic Paon; Jonathan Sleeman
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

10.  Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.

Authors:  Kyung N Lee; Kenneth W Jackson; Simon Terzyan; Victoria J Christiansen; Patrick A McKee
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.